S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
NIH to fund unproven ALS drugs under patient-backed law
NYSE:HQL

Tekla Life Sciences Investors - HQL Stock Forecast, Price & News

$13.66
-0.04 (-0.29%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.55
$14.01
50-Day Range
$13.39
$16.31
52-Week Range
$13.03
$21.64
Volume
54,756 shs
Average Volume
74,934 shs
Market Capitalization
$343.41 million
P/E Ratio
N/A
Dividend Yield
10.73%
Price Target
N/A
HQL stock logo

About Tekla Life Sciences Investors (NYSE:HQL) Stock

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Receive HQL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tekla Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.

HQL Stock News Headlines

HQL: A Biotechnology Equity CEF With No Leverage
Tekla Life Sciences cuts dividend by 10% to $0.35
5 Dividend Funds Yielding Up To 27.2%
Tekla Life Sciences Investors Declares Cash Distribution
Tekla Life Sciences Investors Declares Distribution
HQH: Deep Discount Leads To High Yield
HQL TeklaLife Sciences Investors Common Stock
Tekla Life Sciences declares $0.39 dividend
Tekla Life Sciences Investors Declares Stock Distribution
Top Picks 2020- Tekla Life Sciences Fund HQL
Tekla Life Sciences Investors
Tekla Life Sciences Investors of Benef Interest
Tekla Life Sciences Investors (HQL)
Top Picks 2019- Tekla Life Sciences Investors HQL
See More Headlines
Receive HQL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tekla Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.

HQL Company Calendar

Ex-Dividend for 9/30 Dividend
8/25/2022
Dividend Payable
9/30/2022
Today
10/02/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Investment offices, not elsewhere classified
Sub-Industry
N/A
Sector
Finance
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
22,615,000
Market Cap
$343.41 million
Optionable
Not Optionable
Beta
0.82

Key Executives

  • Dr. Daniel R. Omstead M.SDr. Daniel R. Omstead M.S (Age 69)
    Ph.D., Principal Exec. Officer, Pres and Trustee













HQL Stock - Frequently Asked Questions

How have HQL shares performed in 2022?

Tekla Life Sciences Investors' stock was trading at $19.23 at the beginning of the year. Since then, HQL shares have decreased by 29.0% and is now trading at $13.66.
View the best growth stocks for 2022 here
.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a increase in short interest in September. As of September 15th, there was short interest totaling 36,300 shares, an increase of 80.6% from the August 31st total of 20,100 shares. Based on an average trading volume of 74,500 shares, the days-to-cover ratio is currently 0.5 days.
View Tekla Life Sciences Investors' Short Interest
.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors announced a quarterly dividend on Wednesday, August 17th. Shareholders of record on Friday, August 26th will be paid a dividend of $0.31 per share on Friday, September 30th. This represents a $1.24 annualized dividend and a yield of 9.08%. The ex-dividend date is Thursday, August 25th.
Read our dividend analysis for HQL
.

Is Tekla Life Sciences Investors a good dividend stock?

Tekla Life Sciences Investors (NYSE:HQL) pays an annual dividend of $1.47 per share and currently has a dividend yield of 10.73%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HQL.

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $13.66.

How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors (NYSE:HQL) has a market capitalization of $343.41 million.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The official website for the company is www.teklacap.com. The company can be reached via phone at (617) 772-8500, via email at info@teklacap.com, or via fax at 617-772-8577.

This page (NYSE:HQL) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.